A decision aid for GPs for the treatment of elderlymale patients with lower urinary tract symptoms (LUTS)

Family Practice

Volumn 23, Issue 6, 2006, Pages 666-673

  Norg, Roelf J C ^a   Portegijs, Piet J M ^a   van de Beek, Kees ^b   van Schayck, Onno ^a   Knottnerus, J André ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Benign prostatic hyperplasia; Diagnosis; Lower urinary tract symptoms; Therapy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CHOLESTENONE 5ALPHA REDUCTASE; CREATININE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD; CLINICAL PRACTICE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DECISION SUPPORT SYSTEM; DRUG ANTAGONISM; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH SURVEY; HOSPITALIZATION; HUMAN; MALE; MALE GENITAL SYSTEM SURGERY; METHODOLOGY; MIDDLE AGED; PATIENT REFERRAL; QUALITY OF LIFE; QUESTIONNAIRE; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TREATMENT OUTCOME; URINARY TRACT DISEASE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; BIOLOGICAL MARKERS; CHOLESTENONE 5 ALPHA-REDUCTASE; COHORT STUDIES; CREATININE; CROSS-SECTIONAL STUDIES; DECISION SUPPORT TECHNIQUES; FAMILY PRACTICE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; QUALITY OF LIFE; QUESTIONNAIRES; REFERRAL AND CONSULTATION; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UROLOGIC DISEASES; UROLOGIC SURGICAL PROCEDURES, MALE;

EID: 36048941750     PISSN: 02632136     EISSN: 14602229     Source Type: Journal    
DOI: 10.1093/fampra/cml028     Document Type: Article

References (8)

1. Prescription Cost Analysis: Department of Health. Bulletin 2004-12; ISBN 1 84182 866 1 and 1 84182 710 X; Publication date: 30 June 2004. Available at: http://www.dh.gov.uk/healthcarestatistics.
2. De la Rosette JJ, Madersbacher S, Alizivatos G, Rioja Sanz C, Emberton M, Nordling J. Guideline on benign prostatic hyperplasia: European Association of Urology; December 2004. Available at: http://www.uroweb.org/files/uploaded_ files/BPHDec2004Webversion.pdf.
3. Speakman MJ, Kirby RS, Joyce A, Abrams P, Pocock R. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004; 93: 985-990.
4. Bruskewitz R. Management of symptomatic BPH in the US:who is treated and how? Eur Urol 1999; 36 (Suppl. 3): 7-13.
5. Wolters RJ, Spigt MG, van Reedt Dorland PFH et al. NHG-Standaard Bemoeilijkte mictie bij oudere mannen. Huisarts en Wetenschap 2004; 47: 571-586.
6. Stoevelaar HJ, Van de Beek C, Casparie AF, McDonnell J, Nijs HG. Treatment choice for benign prostatic hyperplasia: a matter of urologist preference? JUrol1999; 161: 133-138.
7. McDonnell J, Stoevelaar HJ, Bosch JL, Kahan JP. The appropriateness of treatment of benign prostatic hyperplasia: a comparison of Dutch and multinational criteria. Health Policy 2001; 57: 45-56.
8. American Urologic Association. Guideline on the management of Benign Prostatic Hyperplasia (BPH). Available at: http://www.auanet.org/guidelines/bph.cfm.